Renaissance Technologies's TOI Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 721,900 shares of The Oncology Institute, Inc. (TOI) worth $2.57 M, representing 0.00% of the portfolio. First purchased in 2023-Q1, this medium-term investment has been held for 12 quarters.
Based on 13F filings, Renaissance Technologies has maintained a strategic position in TOI, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 293,000 shares. Largest reduction occurred in Q3 2024, reducing 169,400 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's The Oncology Institute (TOI) Holding Value Over Time
Track share changes against reported price movement
Quarterly The Oncology Institute (TOI) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -28,600 | Reduce 3.81% | 721,900 | $3.56 |
| Q3 2025 | +293,000 | Add 64.04% | 750,500 | $3.49 |
| Q2 2025 | +209,900 | Add 84.77% | 457,500 | $2.05 |
| Q1 2025 | +65,600 | Add 36.04% | 247,600 | $1.14 |
| Q4 2024 | +12,000 | Add 7.06% | 182,000 | $0.31 |
| Q3 2024 | -169,400 | Reduce 49.91% | 170,000 | $0.33 |
| Q2 2024 | +199,300 | Add 142.26% | 339,400 | $0.46 |
| Q1 2024 | +50,800 | Add 56.89% | 140,100 | $1.58 |
| Q4 2023 | +17,000 | Add 23.51% | 89,300 | $2.04 |
| Q3 2023 | -3,342 | Reduce 4.42% | 72,300 | $1.40 |
| Q2 2023 | -56,858 | Reduce 42.91% | 75,642 | $0.00 |
| Q1 2023 | +132,500 | New Buy | 132,500 | $0.00 |
Renaissance Technologies's The Oncology Institute Investment FAQs
Renaissance Technologies first purchased The Oncology Institute, Inc. (TOI) in Q1 2023, acquiring 132,500 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held The Oncology Institute, Inc. (TOI) for 12 quarters since Q1 2023.
Renaissance Technologies's largest addition to The Oncology Institute, Inc. (TOI) was in Q3 2025, adding 750,500 shares worth $2.62 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 721,900 shares of The Oncology Institute, Inc. (TOI), valued at approximately $2.57 M.
As of the Q4 2025 filing, The Oncology Institute, Inc. (TOI) represents approximately 0.00% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in The Oncology Institute, Inc. (TOI) was 750,500 shares, as reported at the end of Q3 2025.